🔗 Share this article World Health Organization Raises Warning Over Acute Lack of Obesity Injections Fewer than a tenth of patients who could benefit from obesity jabs like Wegovy have access to them, caution the WHO as it issues its initial advice on the drugs. Considering in excess of 1,000,000,000 people worldwide currently obese, it is calling for more widespread and fairer access to GLP-1 medication. According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention. "The latest guidance affirms that obesity is a chronic disease that can be addressed with thorough and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are significant barriers to universal access to the injections that can help people shift substantial weight, notes the agency. Weight-Loss Drug Supply Crisis Even under the present most optimistic case, the supply of such drugs would only suffice for approximately 100 million people – less than 10% of eligible patients, as stated by the WHO. The advice urges countries and companies to increase availability, through approaches like patent sharing. A patent on the active ingredient – the core ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026. The Way Obesity Drugs Function The injections mimick a body's own hormone to reduce digestion speed, suppress the appetite and enhance satiety so users consume fewer calories. Patients usually start to lose weight within a few weeks of starting on the weekly injections. Research suggests users may see weight return after a year of halting the treatment, because their usual hunger come back. Being overweight or obese elevates your likelihood for contracting diseases, including diabetes, cardiovascular issues, brain attack, and specific cancers. Excess weight concerns individuals in every country and was responsible for millions of deaths worldwide in 2024, as per the health agency.
Fewer than a tenth of patients who could benefit from obesity jabs like Wegovy have access to them, caution the WHO as it issues its initial advice on the drugs. Considering in excess of 1,000,000,000 people worldwide currently obese, it is calling for more widespread and fairer access to GLP-1 medication. According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention. "The latest guidance affirms that obesity is a chronic disease that can be addressed with thorough and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are significant barriers to universal access to the injections that can help people shift substantial weight, notes the agency. Weight-Loss Drug Supply Crisis Even under the present most optimistic case, the supply of such drugs would only suffice for approximately 100 million people – less than 10% of eligible patients, as stated by the WHO. The advice urges countries and companies to increase availability, through approaches like patent sharing. A patent on the active ingredient – the core ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026. The Way Obesity Drugs Function The injections mimick a body's own hormone to reduce digestion speed, suppress the appetite and enhance satiety so users consume fewer calories. Patients usually start to lose weight within a few weeks of starting on the weekly injections. Research suggests users may see weight return after a year of halting the treatment, because their usual hunger come back. Being overweight or obese elevates your likelihood for contracting diseases, including diabetes, cardiovascular issues, brain attack, and specific cancers. Excess weight concerns individuals in every country and was responsible for millions of deaths worldwide in 2024, as per the health agency.